Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. develops and commercializes medical-device and therapy-enabling systems for precise navigation to the brain and spine. Its recurring news includes updates on the FDA-cleared and CE-marked ClearPoint Neuro Navigation System, SmartFrame navigation platform, SmartFlow Neuro Cannula, Velocity Alpha MR High Speed Surgical Drill System, and services that support controlled CNS delivery for cell and gene therapy programs.
Company announcements also cover financial results, product clearances and international regulatory approvals, preclinical development services, biopharma and academic partnerships, and integration of the completed IRRAS Holdings acquisition, which expanded the portfolio into neurocritical care and IRRAflow-related products.
ClearPoint Neuro announced its first-time presentation at the 25th Annual Meeting of the American Society of Gene & Cell Therapy on May 16, 2022. The session will showcase investigational research on gene therapy delivery methods using convection-enhanced delivery. Dr. Ernesto Salegio will present findings in a poster titled AAV Vectors - Preclinical and Proof-of-Concept. ClearPoint aims to demonstrate the feasibility of its technology for targeting and delivering gene therapies while emphasizing the importance of real-time MRI visualization for monitoring.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) reported a record Q1 2022 revenue of $5.0 million, marking a 25% year-over-year increase. The growth was driven by a 30% rise in biologics and drug delivery revenue to $2.2 million. The company expanded its global presence with four additional sites and partnered with Philips for advanced operating room technology. Full-year revenue is now projected between $21.0 million and $22.0 million, translating to a 30-35% growth compared to 2021. Operating expenses rose to $7.1 million, influenced by increased headcount and development costs.
ClearPoint Neuro (CLPT) announces a collaboration with Higgs Boson Health to develop the MyClearPoint™ digital health app. This app aims to enhance drug delivery to the brain and spine and support brain-computer interface surgeries. It will provide patients with essential services, including education and recovery tracking. The partnership leverages Higgs Boson’s proven ManageMySurgery platform, which has shown to improve surgical outcomes and reduce cancellations. This initiative is poised to reduce healthcare resource utilization and improve patient satisfaction.
ClearPoint Neuro has received FDA clearance for version 1.1 of its SmartFrame Array Neuro Navigation System, designed to improve procedures in MRI suites and operating rooms. The system, in limited market release since May 2021, has been utilized in over 50 procedures across 10 clinical sites. The new version includes a pre-planning module to enhance workflow and reduce procedure time. The company's mission focuses on enabling therapies for complex neurological disorders. The SmartFrame Array's enhanced features aim to streamline clinical trial processes.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced an expansion of its licensing agreement with Philips to incorporate Computed Tomography (CT) into its surgical navigation system. This aims to enhance surgical procedures in the Operating Room (OR), utilizing the ClearPoint Maestro™ Brain Model for improved accuracy. The integration will facilitate the training of surgeons and allow workflows to mirror those used in MRI environments. ClearPoint's navigation system has FDA clearance and is operational in around 60 sites globally, supporting various neurological treatments.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced it will release its financial results for Q1 2022 on May 11, 2022, post-market. Investors can join a live review at 4:30 p.m. ET the same day via a conference call or online. The company focuses on enabling therapies for complex neurological disorders and has FDA clearance for its ClearPoint® Neuro Navigation System, operational in approximately 60 sites across the US, Canada, and Europe. ClearPoint is also engaged with about 40 biologics/pharmaceutical firms for CNS therapeutic delivery.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced its participation in the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference on April 7, 2022, at 2:30 p.m. Eastern Time. The company specializes in navigating and delivering therapies to treat complex neurological disorders with precision. Its FDA-cleared ClearPoint® Neuro Navigation System is in around 60 active sites across North America and Europe. Currently, ClearPoint is collaborating with approximately 40 pharmaceutical firms and has supported over 5,000 clinical cases globally.
ClearPoint Neuro reported record revenues for Q4 2021, achieving $4.3 million, a 15% increase from Q4 2020. For the full year, revenue reached $16.3 million, marking a 27% growth over 2020. The firm highlighted a robust 31% rise in biologics and drug delivery revenue, totaling $6.8 million. Despite challenges from COVID-19, ClearPoint supported 929 cases in 2021 and ended the year with $54.1 million in cash. The company anticipates revenue between $20 to $22 million for 2022, fueled by strategic expansions and FDA clearances.
ClearPoint Neuro announced preliminary financial results for Q4 and full year 2021. Q4 revenue reached $4.3 million, up 15% year-over-year, driven by a 37% increase in neurosurgery products to $2.1 million. Full year revenue hit $16.3 million, a 27% rise, supported by a record 929 cases handled. The company projects 2022 revenue of $20.0-$22.0 million, marking a 23%-35% growth. However, COVID-19's impact on elective procedures remains a key risk. The earnings call is scheduled for March 1, 2022, after market close.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022. A pre-recorded presentation will be available from 7 a.m. ET. The company focuses on enhancing treatment for complex neurological disorders through its FDA-cleared ClearPoint Neuro Navigation System, operational at over 60 sites across the U.S., Canada, and Europe. ClearPoint has partnered with around 40 companies and has supported over 5,000 clinical cases, providing precise delivery of therapies and innovations in the field.